A new frontier AI company called Recursive Superintelligence has emerged from stealth with $650 million in funding and an ...

Claude Sonnet 4, and Gemini 2.5 Pro dynamically — no hardcoded pipelines, fewer tokens than competing frameworks.

Recursive Agents implements a three-phase iterative refinement architecture where LLM agents (instances of Classes) critique and improve their own outputs. Unlike single-pass systems, each agent ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Commonly used AI models fail to accurately diagnose or offer advice for many queries relating to women’s health that require urgent attention. A group of 17 women’s health researchers, pharmacists and ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

One reason Recursion Pharmaceuticals could become a big deal is that its goal is to usher a paradigm shift into the pharmaceutical industry. Even with impressive technological progress over the past ...